Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

The Liver Meeting 2019

- PMLiVE

Gilead’s Trodelvy shows promise in phase 2 bladder cancer study

An estimated 83,000 Americans will be diagnosed with bladder cancer in 2023

- PMLiVE

Novartis’ Cosentyx shows continued improvement in hidradenitis suppurativa patients

An estimated one in 100 people globally are affected by the inflammatory skin disease

- PMLiVE

Gilead’s Trodelvy approved by FDA for metastatic breast cancer

HR+/HER2- is the most common type of breast cancer, accounting for 70% of new cases

- PMLiVE

Gilead’s CAR-T cell therapy recommended by NICE for lymphoma

Yescarta is the first CAR T-cell therapy recommended for routine use on the NHS

- PMLiVE

Gilead and EVOQ Therapeutics partner in deal potentially worth over $650m

The companies will focus on developing therapies for rheumatoid arthritis and lupus

- PMLiVE

Kite announces acquisition of Tmunity Therapeutics in latest agreement

The acquisition will include Tmunity’s ‘armoured’ CAR T technology platform

- PMLiVE

Novartis receives EC approval for Pluvicto to treat adult cancer patients

Patients receiving Pluvicto plus best standard of care had a 38% reduction in the risk of death

- PMLiVE

Novartis’ iptacopan shows promise as rare blood disease treatment in phase 3 study

Around 82.3% of patients achieved haemoglobin-level increases of 2g/dL or more from baseline

- PMLiVE

Novartis partners with Cancer Research UK for rare cancer trial

The trial enrolled both paediatric and adult patients with any rare form of cancer

- PMLiVE

Novartis announces positive phase 3 results for prostate cancer drug Pluvicto

The study met its primary endpoint of radiographic progression-free survival

- PMLiVE

Novartis and MMV to advance new malaria drug combination to phase 3 study

The announcement comes as the threat of resistance to current malaria treatments grows

- PMLiVE

Novartis’ Cosentyx receives MHRA approval for two types of juvenile idiopathic arthritis

A phase 3 trial showed significantly longer time to flare for both JPsA and ERA patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links